| Patent application number | Description | Published |
|---|
| 20080206345 | Methods for Control of Soil-Dwelling Pests and/or Soil-Borne Diseases - A method for the control of soil-dwelling pests and/or soil-borne diseases comprising treating a plant propagation material with an effective amount of the pesticidal composition and/or applying an effective amount of a pesticidal composition to a locus where control is desired, provided that the composition comprises, as active ingredient, one or more pesticides (A) having a water solubility of at most 100 μg/litre, at 25° C. at neutral pH, and at least one formulation auxiliary, wherein the size of particles in the composition is in the range 3.60 μm to 0.70 μm at X | 08-28-2008 |
| 20100173776 | METHOD FOR ENHANCING PLANT TOLERANCE - A method of increasing functional protein activity in a plant comprising applying to the plant, part of the plant, the plant propagation material thereof and/or a surrounding area thereof an effective amount of one or more neonicotinoid compounds selected from thianicotinyl compounds and tetrahydrofuranyl compounds. | 07-08-2010 |
| 20100173959 | METHOD OF PROTECTING A PLANT PROPAGATION MATERIAL, A PLANT, AND/OR PLANT ORGANS - A method of controlling or preventing pest damage in a plant propagation material, a plant, and/or plant organs that grow at a later point in time, which comprises applying on the plant propagation material or locus thereof a compound I or II represented by formula (I) and (II) wherein R1 is represented, for example, by H; R6 is represented, for example, by H; R2 is represented, for example, by halogen; R3 to R5 is represented, for example, by H; and n is either 0 or 2; or an enantiomer, diastereomer, or salt, thereof. | 07-08-2010 |
| 20110263429 | Pesticidal Combinations - A combination, suitable for agricultural use comprises (I) a compound of formula (X) and (II) one or more agents selected, independently of each other, from any one of (A) to (G):
| 10-27-2011 |
| 20110319262 | PESTICIDAL COMBINATIONS CONTAINING SULFOXAFLOR - A combination, suitable for agricultural use comprising (I): a compound of formula (X) and (II): one or more agents selected, independently of each other, from any one of (A) to (G): (A) a certain fungicide; (B) a certain insecticide and/or nematicide; (C) a certain protein produced by the plant pathogenic bacterium, | 12-29-2011 |
| Patent application number | Description | Published |
|---|
| 20090117120 | Transgenic animal model for alzheimer's disease - Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-β (Aβ) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening for therapeutic or diagnostic agents useful in the treatment or diagnosis of Alzheimer's disease, in particular for improving blood flow to the brain are provided as well as the corresponding therapeutic methods. | 05-07-2009 |
| 20100169988 | MEANS AND METHODS FOR ISOLATING AND DETERMINING NOVEL TARGETS FOR THE TREATMENT OF NEURODEGENERATIVE, NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS AND COMPOSITIONS COMPRISING THE SAME - A novel method of identifying and obtaining molecules interacting with neurodegenerative, neurological or neuropsychiatric disorder-associated proteins is provided, which is suitable for drug screening and drug development. Furthermore, drugs and drug targets for the therapeutic intervention of neurodegenerative, neurological or neuropsychiatric disorders, in particular Alzheimer's disease are described. | 07-01-2010 |
| 20100172919 | NOVELTREATMENT FOR NEUROLOGICAL DISORDERS - Provided are novel drugs and methods in the treatment as well as diagnosis of neurological disorders such as Alzheimer's disease and amyloid-beta pathology/amyloidosis. More specifically, the use of erythropoietin and analogs thereof for the treatment of Aβ peptide related brain impairments is described. Furthermore, the use of claudin-5 and variants thereof as biomarker for Alzheimer's disease and for the progression of Alzheimer's disease, respectively, is provided. | 07-08-2010 |
| 20100297108 | METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS - A novel treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are also described, wherein ex vivo stimulated antigen-selected peripheral blood lymphocytes are regrafted into the cognate donor. | 11-25-2010 |
| Patent application number | Description | Published |
|---|
| 20100202968 | Method of Providing Disease-Specific Binding Molecules and Targets - Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described. | 08-12-2010 |
| 20110300077 | Human Anti-Alpha-Synuclein Antibodies - Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively. | 12-08-2011 |
